Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
Investors purchased shares at a fixed price, without variable-price or reset features.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Telomir Pharmaceuticals (TELO) secured approximately $5.6 million through a private placement of common stock to support development of Telomir-Zn.
The company issued 4,843,300 shares at $1.16 per share, a 5% discount to the applicable 10-day volume-weighted average price. Gross proceeds are before placement agent fees and other offering expenses. Existing shareholder John Paul DeJoria invested an additional $1.0 million. No investor warrants or convertible securities accompanied the shares.
Telomir intends to use net proceeds primarily for Telomir-Zn’s Phase 1/2 program in advanced or metastatic triple-negative breast cancer. The FDA has cleared the application allowing human testing. Phase 1 will assess safety, tolerability and dose selection; the Phase 2 expansion is designed to focus on efficacy. The financing also supports working capital and general corporate purposes.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointApproximately $5.6 million in gross proceeds adds capital before fees and offering expenses. 6.7% of market cap
- Moderate pointFDA clearance enables the first-in-human Phase 1/2 trial in advanced or metastatic triple-negative breast cancer.
- Minor pointNo investor warrants or convertible securities accompanied the common-stock financing.
- Minor pointJohn Paul DeJoria invested an additional $1.0 million as an existing shareholder.
- Minor point. Forward-looking: it has not happened yet and may not happen.Net proceeds are intended primarily to support Telomir-Zn’s Phase 1/2 clinical development.
- Minor pointPreclinical studies demonstrated inhibition of multiple iron-dependent histone demethylases, enzymes involved in gene regulation.
Negative
- Moderate point4,843,300 new common shares at $1.16 each dilute existing shareholders.
- Minor point$1.16 purchase price represents a 5% discount to the applicable 10-day volume-weighted average price.
- Minor pointPlacement agent fees and other offering expenses reduce proceeds available to Telomir.
News Explained
The resale-registration filing is an agreed obligation, separate from the already completed issuance.
Telomir has issued 4,843,300 common shares for approximately
A private placement is a sale of securities to selected investors outside a public offering; Telomir separately agreed to file a registration statement covering resale of the issued shares, subject to the registration-rights agreement.
Details
Market move: TELO +5.79% vs previous close. common stock PIPE financing
On Oct 6, the day this news came out, the latest delayed price for TELO is 5.79% above the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $1.28. Relative volume is exceptionally heavy at 21.9x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Gross proceeds
- approximately $5.6 million
- PIPE financing, before fees and offering expenses
- DeJoria investment
- $1.0 million
- Additional investment in the financing
- Common shares issued
- 4,843,300 shares
- PIPE financing
- Purchase price
- $1.16 per share
- Fixed price in the financing
- Discount to VWAP
- 5%
- Applicable 10-day volume-weighted average price
Key Terms
pipe financial
vwap financial
triple-negative breast cancer medical
open-label medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Common Stock PIPE Strengthens Telomir’s Capital Position as Company Advances Telomir-Zn into Clinical Development Under FDA-Cleared IND in Triple-Negative Breast Cancer (TNBC)
MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, today announced an approximately
The financing includes an additional
DeJoria most recently reported beneficial ownership of approximately 3.55 million shares, representing approximately
“I have always looked for opportunities that can do the greatest good for the greatest number of people, and that is part of what attracted me to Telomir,” said John Paul DeJoria. “Cancer continues to take an enormous toll on patients and families, and there remains a need for new approaches that can potentially improve the way we treat this disease. Telomir is pursuing a different scientific approach, and with the Company now moving into human clinical trials, I am pleased to increase my investment and support the team as they work to determine what Telomir-Zn may be able to do for patients.”
Alexander Capital, L.P. acted as placement agent for the financing. The Company expects to receive aggregate gross proceeds of approximately
Financing Terms
Under the terms of the financing, Telomir issued 4,843,300 shares of common stock at a purchase price of
Investors in the financing purchased common stock at a fixed price, with no accompanying investor warrants, convertible securities, or variable-price or reset features.
The securities were issued in a private placement. Telomir has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares issued in the financing, subject to the terms of the Registration Rights Agreement.
The Company intends to use the net proceeds primarily to support the clinical development of Telomir-Zn, including its Phase 1/2 clinical program in advanced or metastatic triple-negative breast cancer (TNBC), as well as for working capital and general corporate purposes.
“We have been very deliberate about how and when we access the capital markets,” said Erez Aminov, Chairman and CEO of Telomir. “Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders. As Telomir enters clinical development, our focus is on execution: deploying this capital efficiently to advance Telomir-Zn through its Phase 1/2 clinical program, generate meaningful human data and position the Company strongly for the milestones ahead.”
Strengthening Telomir’s Position for Clinical Execution
The financing comes as Telomir advances Telomir-Zn, its lead investigational oral small molecule, into human clinical evaluation. The U.S. Food and Drug Administration has cleared Telomir’s Investigational New Drug (IND) application for Telomir-Zn, enabling the Company to proceed with its first-in-human Phase 1/2 clinical trial in patients with advanced or metastatic TNBC.
TNBC is an aggressive form of breast cancer defined by the absence of three common therapeutic targets, estrogen receptors, progesterone receptors, and HER2, limiting the applicability of many targeted treatments used in other forms of breast cancer. Patients with advanced or metastatic disease continue to face a significant need for additional treatment options.
The multicenter, open-label Phase 1/2 study is designed to move Telomir-Zn from initial human dosing through dose selection and into an efficacy-focused expansion. The Phase 1 portion will evaluate safety, tolerability, and dose selection while also assessing pharmacodynamic biomarkers and preliminary signals of antitumor activity. The Phase 2 expansion is designed to build on those findings with a greater focus on efficacy, providing an initial clinical proof-of-concept assessment of Telomir-Zn in advanced or metastatic TNBC.
A New Epigenetic Approach to Treating Cancer
Telomir-Zn is being developed as a potentially first-in-class oral epigenetic therapy designed to modulate intracellular metal homeostasis, particularly iron and copper, and influence gene-control pathways implicated in cancer. Preclinical studies have demonstrated inhibition of multiple iron-dependent histone demethylases (KDMs), supporting the Company’s hypothesis that Telomir-Zn may help restore more normal epigenetic regulation and potentially reactivate tumor-suppressor pathways that cancer has silenced.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The Company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received Investigational New Drug clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic triple-negative breast cancer. For more information, please visit https://telomirpharma.com/.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking statements include these words.
Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, clinical utility, market opportunity, and future development of Telomir-1 (Telomir-Zn) and the Company’s other product candidates. Forward-looking statements may also include statements regarding the anticipated closing of the financing described herein, the expected proceeds from and intended use of such proceeds, the significance of the published preclinical findings, the relevance of such findings to the Company’s oncology development programs, the advancement of the Company’s Phase 1/2 TNBC clinical trial, and the potential applicability of Telomir-Zn across multiple disease areas.
These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s other filings with the U.S. Securities and Exchange Commission (“SEC”).
Forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at the SEC website and in the “Investors” section of our website, for a discussion of these and other risks and uncertainties.
Private Placement Disclosure
The securities described in this press release are being offered and sold in a private placement and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws.
The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission covering the resale of the shares of common stock issued in the private placement, subject to the terms and conditions of the applicable registration rights agreement.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
Contact Information
Krystina Quintana
Email: info@telomirpharma.com
Phone: (786) 396-6723
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did Telomir raise in its common-stock financing, and at what price?
Telomir secured approximately $5.6 million in gross proceeds by issuing 4,843,300 common shares at $1.16 per share. The price represents a 5% discount to the applicable 10-day volume-weighted average price. Gross proceeds are before placement agent fees and other offering expenses.
What will Telomir’s Phase 1/2 trial of Telomir-Zn evaluate?
The multicenter, open-label trial will evaluate Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer. Beyond safety, tolerability and dose selection, Phase 1 will assess biomarkers of the drug’s effects and preliminary signs of antitumor activity. The Phase 2 expansion is designed to provide an initial clinical assessment of efficacy.